novaPROX Combo

Key Points

  • Probiotic combination assessed in a prostate - organoid model - the best in vitro model to mimic what happen in the human body
  • Demonstrated effective in the organoid model under induced prosta- tic hyperplasia condition
  • Scientific study under writing for peer-review publication (expected submission Nov-22, publication Jan-23) IF >6
  • Patented probiotic strain and patent application for “novaPROX” probiotic combo
  • Clinical trial in double-arms, randomized placebo-controlled study is ongoing to evaluate the complementary treatment of Benign Prosta- tic Hyperplasia with novaPROX alongside the drug treatment (Duta- steride, Finasteride or Serenoa repens)
  • Without food allergens Reg. 1169/2011
  • Available as premix, standardized at 100 billion

PROBIOTIC COMBINATION TO RESTORE PHYSIOLOGICAL BALANCE IN CASE OF BENIGN PROSTATIC HYPERPLASIA

B. psychraerophilum Q5 (DSM 33131) B. longum novaBLG1 (DSM 34338)

Recommended dosage: 2 billion live probiotic cells per day

Experimental Setting

Probionova nextgen collection was investigated to evaluate the influence of probiotics on prostate cell overgrowth. Firstly, it was conducted a dose-response screening study on a prostate cell line to select the best active combination. A second phase study was then conducted using the gut-prostate organoid model under induced prostatic hyperplasia condition - this in vitro setting is the most predictive preclinical model.

The prostatic organoids were pre-treated with testosterone 0.5μM in order to mimic prostatic hyperplasia condition.

Scientific Data

  • novaPROX resulted very effective in reducing the uncontrolled proliferation of prostatic cells.
  • Reduces the damages of oxidative stress and inflammation caused by the induced hyperplasia condition, resulting in a physiological amelioration of BPH-associated markers.
  • Working together, the probiotic strains Q5 and novaBLG1 regulate the function of the androgen receptor (hyperactivated in case of hyperplasia), regulating testosterone and serotonin levels and restoring their balance (markers evaluated: Ki67, androgen receptor activity, level of testosterone, 5Htr1a receptor, serotonin level, PSA).
  • The Prostatic Specific Antigen (PSA) is a sensitive and specific marker for prostatic diseases, in which it is increased. PSA is produced during hyperplasia condition, but the novaPROXcombo can reduce this production (p<0.05) suggesting a strong positive role during BPH.
  • All these important effects are probably due to the presence of SCFAs secreted by probiotics, for example butyric acid, capable to act as second messengers and to activate various mechanisms that are impaired during the disease.

Key Points

  • Probiotic combination assessed in a prostate - organoid model - the best in vitro model to mimic what happen in the human body
  • Demonstrated effective in the organoid model under induced prosta- tic hyperplasia condition
  • Scientific study under writing for peer-review publication (expected submission Nov-22, publication Jan-23) IF >6
  • Patented probiotic strain and patent application for “novaPROX” probiotic combo
  • Clinical trial in double-arms, randomized placebo-controlled study is ongoing to evaluate the complementary treatment of Benign Prosta- tic Hyperplasia with novaPROX alongside the drug treatment (Duta- steride, Finasteride or Serenoa repens)
  • Without food allergens Reg. 1169/2011
  • Available as premix, standardized at 100 billion
IT EN